HC Wainwright Brokers Raise Earnings Estimates for PDSB

PDS Biotechnology Corporation (NASDAQ:PDSB) – Investment analysts at HC Wainwright upped their Q2 2026 earnings estimates for PDS Biotechnology in a research note issued to investors on Wednesday, May 13th. HC Wainwright analyst J. Pantginis now forecasts that the company will earn ($0.14) per share for the quarter, up from their previous forecast of ($0.17). HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for PDS Biotechnology’s current full-year earnings is ($0.57) per share. HC Wainwright also issued estimates for PDS Biotechnology’s Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at ($0.17) EPS, FY2026 earnings at ($0.60) EPS, FY2027 earnings at ($0.61) EPS and FY2028 earnings at ($0.49) EPS.

PDS Biotechnology (NASDAQ:PDSB) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.02.

Several other brokerages also recently weighed in on PDSB. Weiss Ratings reiterated a “sell (e+)” rating on shares of PDS Biotechnology in a research note on Tuesday, April 21st. Wall Street Zen upgraded shares of PDS Biotechnology from a “sell” rating to a “hold” rating in a research note on Saturday, April 4th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $9.00.

PDS Biotechnology Price Performance

Shares of PDSB opened at $1.18 on Tuesday. PDS Biotechnology has a fifty-two week low of $0.51 and a fifty-two week high of $1.92. The company has a market capitalization of $65.87 million, a price-to-earnings ratio of -1.76 and a beta of 1.51. The firm has a 50-day simple moving average of $0.92 and a 200-day simple moving average of $0.87. The company has a debt-to-equity ratio of 2.73, a quick ratio of 2.26 and a current ratio of 2.26.

Institutional Investors Weigh In On PDS Biotechnology

Hedge funds have recently made changes to their positions in the business. Tempus Wealth Planning LLC raised its holdings in PDS Biotechnology by 29.3% during the fourth quarter. Tempus Wealth Planning LLC now owns 61,800 shares of the company’s stock worth $48,000 after purchasing an additional 14,000 shares in the last quarter. Virtu Financial LLC purchased a new position in PDS Biotechnology during the fourth quarter worth about $25,000. Geode Capital Management LLC raised its holdings in PDS Biotechnology by 8.0% during the fourth quarter. Geode Capital Management LLC now owns 520,398 shares of the company’s stock worth $401,000 after purchasing an additional 38,399 shares in the last quarter. Renaissance Technologies LLC raised its holdings in PDS Biotechnology by 25.0% during the first quarter. Renaissance Technologies LLC now owns 220,800 shares of the company’s stock worth $134,000 after purchasing an additional 44,100 shares in the last quarter. Finally, Marshall Wace LLP purchased a new position in PDS Biotechnology during the second quarter worth about $91,000. Institutional investors and hedge funds own 26.84% of the company’s stock.

About PDS Biotechnology

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.